Global extent of chloroquine-resistant Plasmodium vivax: A systematic review and meta-analysis

The Lancet Infectious Diseases

Volumn 14, Issue 10, 2014, Pages 982-991

  Price, Ric N ^a,b   von Seidlein, Lorenz ^b   Valecha, Neena ^c   Nosten, Francois ^a,d,e   Baird, J Kevin ^a,f   White, Nicholas J ^a,e  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^c NATIONAL INSTITUTE OF MALARIA RESEARCH   (India)

^d SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^e MAHIDOL OXFORD TROPICAL MEDICINE RESEARCH UNIT   (Thailand)

^f OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER; BENFLUMETOL; CHLOROQUINE; CHLOROQUINE PLUS PRIMAQUINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; DOXYCYCLINE; HALOFANTRINE; MEFLOQUINE; PYRIMETHAMINE; PYRIMETHAMINE PLUS SULFADOXINE; SULFADOXINE; TAFENOQUINE; ANTIMALARIAL AGENT;

ANTIMALARIAL DRUG RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; CONTINUOUS INFUSION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG QUALITY; DRUG TREATMENT FAILURE; ENDEMIC DISEASE; HUMAN; INFECTION PREVENTION; LOW DRUG DOSE; META ANALYSIS; MICROSCOPY; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; PARASITE CLEARANCE; PARASITEMIA; PATIENT ASSESSMENT; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; BLOOD; DRUG COMBINATION; DRUG EFFECTS; DRUG RESISTANCE; HEALTH; ISOLATION AND PURIFICATION; MALARIA, VIVAX; PARASITOLOGY; PHYSIOLOGY; RECURRENT DISEASE; TREATMENT OUTCOME;

ANTIMALARIALS; CHLOROQUINE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; GLOBAL HEALTH; HUMANS; MALARIA, VIVAX; PLASMODIUM VIVAX; RECURRENCE; TREATMENT OUTCOME;

EID: 84908134087     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)70855-2     Document Type: Article

References (45)

1. Mendis K, Sina BJ, Marchesini P, Carter R The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 2001, 64:97-106.
2. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM Vivax malaria: neglected and not benign. Am J Trop Med Hyg 2007, 77:79-87.
3. McGready R, Lee SJ, Wiladphaingern J, et al. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis 2012, 12:388-396.
4. Barcus MJ, Basri H, Picarima H, et al. Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua. Am J Trop Med Hyg 2007, 77:984-991.
5. Rodriguez-Morales AJ, Benitez JA, Arria M Malaria mortality in Venezuela: focus on deaths due to Plasmodium vivax in children. J Trop Pediatr 2008, 54:94-101.
6. Tjitra E, Anstey NM, Sugiarto P, et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med 2008, 5:e128.
7. Baird JK Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin Microbiol Rev 2013, 26:36-57.
8. White NJ The assessment of antimalarial drug efficacy. Trends Parasitol 2002, 18:458-464.
9. Rieckmann KH, Davis DR, Hutton DC Plasmodium vivax resistance to chloroquine?. Lancet 1989, 2:1183-1184.
10. Baird JK, Basri H, Purnomo, et al. Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am J Trop Med Hyg 1991, 44:547-552.
11. Price RN, Auburn S, Marfurt J, Cheng Q Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax. Trends Parasitol 2012, 28:522-529.
12. Price RN, Douglas NM, Anstey NM New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis 2009, 22:430-435.
13. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6:e1000097.
14. Clinical trials review Worldwide Antimalarial Resistance Network, (accessed June 28, 2014). http://www.wwarn.org/resistance/malaria/literature/overview.
15. Chloroquine resistant Plasmodium vivax Worldwide Antimalarial Resistance Network, (accessed Sept 4, 2014). http://www.wwarn.org/en/resistance/malaria/literature/chloroquine-resistant-plasmodium-vivax.
16. Baird JK, Leksana B, Masbar S, et al. Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg 1997, 56:621-626.
17. Methods for surveillance of antimalarial drug efficacy; 2009 2009, WHO, World Health Organization, Geneva, (accessed August 20, 2014). http://whqlibdoc.who.int/publications/2009/9789241597531_eng.pdf?ua=1.
18. Ratcliff A, Siswantoro H, Kenangalem E, et al. Therapeutic response of multidrug-resistant Plasmodium falciparum and P vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Trans R Soc Trop Med Hyg 2007, 101:351-359.
19. Sumawinata IW, Leksana B, et al. Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. Am J Trop Med Hyg 2003, 68:416-420. Bernadeta.
20. Karunajeewa HA, Mueller I, Senn M, et al. A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med 2008, 359:2545-2557.
21. Genton B, D'Acremont V, Rare L, et al. Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med 2008, 5:e127.
22. Douglas NM, Lampah DA, Kenangalem E, et al. Major burden of severe anemia from non-falciparum malaria species in southern papua: a hospital-based surveillance study. PLoS Med 2013, 10:e1001575.
23. Anstey NM, Douglas NM, Poespoprodjo JR, Price RN Plasmodium vivax: clinical spectrum, risk factors and pathogenesis. Adv Parasitol 2012, 80:151-201.
24. White NJ Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J 2011, 10:297.
25. Imwong M, Pukrittayakamee S, Gruner AC, et al. Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1. Malar J 2005, 4:20.
26. Chen N, Auliff A, Rieckmann K, Gatton M, Cheng Q Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals. J Infect Dis 2007, 195:934-941.
27. Koepfli C, Mueller I, Marfurt J, et al. Evaluation of Plasmodium vivax genotyping markers for molecular monitoring in clinical trials. J Infect Dis 2009, 199:1074-1080.
28. Barnadas C, Koepfli C, Karunajeewa HA, Siba PM, Davis TM, Mueller I Characterization of treatment failure in efficacy trials of drugs against Plasmodium vivax by genotyping neutral and drug resistance-associated markers. Antimicrob Agents Chemother 2011, 55:4479-4481.
29. Imwong M, Snounou G, Pukrittayakamee S, et al. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis 2007, 195:927-933.
30. Flegg JA, Guerin PJ, White NJ, Stepniewska K Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J 2011, 10:339.
31. White NJ The parasite clearance curve. Malar J 2011, 10:278.
32. Phyo AP, Lwin KM, Price RN, et al. Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial. Clin Infect Dis 2011, 53:977-984.
33. Russell B, Chalfein F, Prasetyorini B, et al. Determinants of in vitro drug susceptibility testing of Plasmodium vivax. Antimicrob Agents Chemother 2008, 52:1040-1045.
34. Pukrittayakamee S, Imwong M, Looareesuwan S, White NJ Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria. Acta Trop 2004, 89:351-356.
35. Baird JK, Hoffman SL Primaquine therapy for malaria. Clin Infect Dis 2004, 39:1336-1345.
36. Leang R, Barrette A, Mey Bouth D, et al. Efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008-2010. Antimicrob Agents Chemother 2013, 57:818-826.
37. Yohannes AM, Teklehaimanot A, Bergqvist Y, Ringwald P Confirmed vivax resistance to chloroquine and effectiveness of artemether-lumefantrine for the treatment of vivax malaria in Ethiopia. Am J Trop Med Hyg 2011, 84:137-140.
38. Ketema T, Getahun K, Bacha K Therapeutic efficacy of chloroquine for treatment of Plasmodium vivax malaria cases in Halaba district, South Ethiopia. Parasit Vectors 2011, 4:46.
39. de Santana Filho FS, Arcanjo AR, et al. Chloroquine-resistant Plasmodium vivax, Brazilian Amazon. Emerg Infect Dis 2007, 13:1125-1126.
40. Srivastava HC, Yadav RS, Joshi H, et al. Therapeutic responses of Plasmodium vivax and P. falciparum to chloroquine, in an area of western India where P. vivax predominates. Ann Trop Med Parasitol 2008, 102:471-480.
41. Singh RK Emergence of chloroquine-resistant vivax malaria in south Bihar (India). Trans R Soc Trop Med Hyg 2000, 94:327.
42. Price RN, Douglas NM, Anstey NM, von Seidlein L Plasmodium vivax treatments: what are we looking for?. Curr Opin Infect Dis 2011, 24:578-585.
43. Ratcliff A, Siswantoro H, Kenangalem E, et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 2007, 369:757-765.
44. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN Artemisinin combination therapy for vivax malaria. Lancet Infect Dis 2010, 10:405-416.
45. John GK, Douglas NM, von Seidlein L, et al. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J 2012, 11:280.